Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Recurrent CDI and Ulcerative Colitis: Single vs Sequential
NCT06071312Phase 2Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allogeneic fecal microbiota in Clostridioides difficile infection (CDI) and ulcerative colitis (UC) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Number of UC patients who will obtain the eradication of rCDI 8 weeks after treatments. Started Sep 2023; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06071312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071312.